The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.
Targeting SphK1 as a New Strategy against Cancer
Open accessAbstract
Sphingolipid metabolites have emerged as critical players in a number of fundamental biological processes. Among them, sphingosine-1-phosphate (S1P) promotes cell survival and proliferation, in contrast to ceramide and sphingosine, which induce cell growth arrest and apoptosis. These sphingolipids with opposing functions are interconvertible inside cells, suggesting that a finely tuned balance between them can determine cell fate. Sphingosine kinases (SphKs), which catalyze the phosphorylation of sphingosine to S1P, are critical regulators of this balance. Of the two identified SphKs, sphingosine kinase type 1 (SphK1) has been shown to regulate various processes important for cancer progression and will be the focus of this review, since much less is known of biological functions of SphK2, especially in cancer. SphK1 is overexpressed in various types of cancers and upregulation of SphK1 has been associated with tumor angiogenesis and resistance to radiation and chemotherapy. Many growth factors, through their tyrosine kinase receptors (RTKs), stimulate SphK1 leading to a rapid increase in S1P. This S1P in turn can activate S1P receptors and their downstream signaling. Conversely, activation of S1P receptors can induce transactivation of various RTKs. Thus, SphK1 may play important roles in S1P receptor RTK amplification loops. Here we review the role of SphK1 in tumorigenesis, hormonal therapy, chemotherapy resistance, and as a prognostic marker. We will also review studies on the effects of SphK inhibitors in cells in vitro and in animals in vivo and in some clinical trials and highlight the potential of SphK1 as a new target for cancer therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Genetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728
Sphingosine-1-phosphate: an enigmatic signalling lipid
Spiegel, S., & Milstien, S. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1103 · Cited by 2,075
Self-citationCetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast Cancer
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052258 · Cited by 1,577
Role of transactivation of the EGF receptor in signalling by G-protein-coupled receptors
Daub, H., Ulrich Weiss, F., Wallasch, C., & Ullrich, A. (1996) · Nature · doi:10.1038/379557a0 · Cited by 1,476
Biologically active sphingolipids in cancer pathogenesis and treatment
Ogretmen, B., & Hannun, Y. A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1411 · Cited by 1,213
Liu, Y., Wada, R., Yamashita, T., Mi, Y., Deng, C.-X., Hobson, J. P., Rosenfeldt, H. M., Nava, V. E., Chae, S.-S., Lee, M.-J., et al. (2000) · Journal of Clinical Investigation · doi:10.1172/jci10905 · Cited by 1,149
Self-citationLee, M.-J., Thangada, S., Claffey, K. P., Ancellin, N., Liu, C. H., Kluk, M., Volpi, M., Sha'afi, R. I., & Hla, T. (1999) · Cell · doi:10.1016/s0092-8674(00)81661-x · Cited by 1,013
Ma, X.-J., Wang, Z., Ryan, P. D., Isakoff, S. J., Barmettler, A., Fuller, A., Muir, B., Mohapatra, G., Salunga, R., Tuggle, J. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.05.015 · Cited by 954
Essential Role for Sphingosine Kinases in Neural and Vascular Development
Mizugishi, K., Yamashita, T., Olivera, A., Miller, G. F., Spiegel, S., & Proia, R. L. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.11113-11121.2005 · Cited by 742
Self-citation
Cited by
An update on sphingosine-1-phosphate and other sphingolipid mediators
Fyrst, H., & Saba, J. D. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.392 · Cited by 344
Nagahashi, M., Ramachandran, S., Kim, E. Y., Allegood, J. C., Rashid, O. M., Yamada, A., Zhao, R., Milstien, S., Zhou, H., Spiegel, S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2167 · Cited by 315
Self-citationRegulation of sphingosine kinase and sphingolipid signaling
Pitson, S. M. (2011) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2010.08.001 · Cited by 307
Cancer-associated lysosomal changes: friends or foes?
Kallunki, T., Olsen, O. D., & Jäättelä, M. (2013) · Oncogene · doi:10.1038/onc.2012.292 · Cited by 298
Schnute, M. E., McReynolds, M. D., Kasten, T., Yates, M., Jerome, G., Rains, J. W., Hall, T., Chrencik, J., Kraus, M., Cronin, C. N., et al. (2012) · Biochemical Journal · doi:10.1042/bj20111929 · Cited by 280
Metadata
- Authors
- Shida, D., Takabe, K., Kapitonov, D., Milstien, S., & Spiegel, S.
- Venue
- Current Drug Targets
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2008-08-01
- Volume
- 9
- Issue
- 8
- Pages
- 662-673
- ISSN
- 1389-4501 (ISSN-L)
- OpenAlex
- W2147245292
- Cited by
- 307
- References
- 98
- FWCI
- 6.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting SphK1 as a New Strategy against Cancer. https://app.cochat.ai/papers/10.2174/138945008785132402
- The paper
- Shida, D., Takabe, K., Kapitonov, D., Milstien, S., & Spiegel, S. (2008). Targeting SphK1 as a New Strategy against Cancer. Current Drug Targets. https://doi.org/10.2174/138945008785132402
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.